Top 75 Things Everyone Gets Wrong About Famous Movies Welcome to WatchMojo, and today we’re counting down our picks for the top 75 misconceptions people have about famous movies. There may be spoilers ...

It appears Braveheart Bio isn’t going to let Big Pharma take away its freedom anytime soon, as the company is aiming for a Nasdaq listing to move its phase 3 cardiovascular drug. The Tuesday IPO ...

Our round-up of biotech financings is led this week by Braveheart Bio, a San Francisco biotech that has launched with $185 million, a lead drug for hypertrophic cardiomyopathy (HCM), and Biogen CEO ...

NEW YORK — Ubiquitous British actor Michael Byrne has died. The Shakespearean performer who appeared in films including "A Bridge Too Far," "Braveheart," "The Saint," "Harry Potter and the Deathly ...

Michael Byrne, the English actor familiar to fans of Indiana Jones and the Last Crusade, Harry Potter and the Deathly Hallows: Part 1, Braveheart, and such British TV series as Coronation Street and ...

Ubiquitous British actor Michael Byrne has died. The Shakespearean performer who appeared in films including “A Bridge Too Far,” “Braveheart,” “The Saint,” “Harry Potter and the Deathly Hallows” and ...

Braveheart Bio is looking to take on Bristol Myers Squibb in hypertrophic cardiomyopathy, while Attovia Therapeutics wants to challenge Sanofi and Regeneron’s Dupixent. Vogenx, meanwhile, is looking ...

Attovia Therapeutics and Braveheart Bio revealed on Tuesday plans to go public, where they’ll aim to add to a recent upswing in big-ticket biotechnology stock offerings. Behind that prospect are two ...

IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news ...

A late clinical-stage cardiovascular biotech focused on hypertrophic cardiomyopathy (HCM). The company is advancing a selective cardiac myosin inhibitor toward global Phase III development as a ...